SPOCK1 Overexpression Suggests Poor Prognosis of Ovarian Cancer.
Autor: | Váncza L; Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary., Horváth A; Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary., Seungyeon L; Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary., Rókusz A; Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary., Dezső K; Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary., Reszegi A; Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, 1085 Budapest, Hungary., Petővári G; Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary., Götte M; Department of Gynecology and Obstetrics, University Hospital Münster, 48149 Münster, Germany., Kovalszky I; Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary., Baghy K; Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary. |
---|---|
Jazyk: | angličtina |
Zdroj: | Cancers [Cancers (Basel)] 2023 Mar 29; Vol. 15 (7). Date of Electronic Publication: 2023 Mar 29. |
DOI: | 10.3390/cancers15072037 |
Abstrakt: | Purpose: Sparc/osteonectin, cwcv, and kazal-like domains proteoglycan 1 (SPOCK1) has been found in a variety of malignant tumors and is associated with a poor prognosis. We aimed to explore the role of SPOCK1 in ovarian cancer. Methods: Ovarian cancer cell lines SKOV3 and SW626 were transfected with SPOCK1 overexpressing or empty vector using electroporation. Cells were studied by immunostaining and an automated Western blotting system. BrdU uptake and wound healing assays assessed cell proliferation and migration. SPOCK1 expression in human ovarian cancer tissues and in blood samples were studied by immunostaining and ELISA. Survival of patients with tumors exhibiting low and high SPOCK1 expression was analyzed using online tools. Results: Both transfected cell lines synthesized different SPOCK1 variants; SKOV3 cells also secreted the proteoglycan. SPOCK1 overexpression stimulated DNA synthesis and cell migration involving p21 CIP1 . Ovarian cancer patients had increased SPOCK1 serum levels compared to healthy controls. Tumor cells of tissues also displayed abundant SPOCK1. Moreover, SPOCK1 levels were higher in untreated ovarian cancer serum and tissue samples and lower in recipients of chemotherapy. According to in silico analyses, high SPOCK1 expression was correlated with shorter survival. Conclusion: Our findings suggest SPOCK1 may be a viable anti-tumor therapeutic target and could be used for monitoring ovarian cancer. |
Databáze: | MEDLINE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |